Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $9.0 million.

  • Coherus Oncology's Consolidated Net Income fell 7561.33% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $540.3 million, marking a year-over-year increase of 21772.8%. This contributed to the annual value of $28.5 million for FY2024, which is 11198.32% up from last year.
  • As of Q3 2025, Coherus Oncology's Consolidated Net Income stood at $9.0 million, which was down 7561.33% from $342.6 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Consolidated Net Income high stood at $342.6 million for Q2 2025, and its period low was -$172.9 million during Q1 2021.
  • Moreover, its 5-year median value for Consolidated Net Income was -$39.6 million (2023), whereas its average is -$1.4 million.
  • As far as peak fluctuations go, Coherus Oncology's Consolidated Net Income tumbled by 58618.86% in 2021, and later soared by 71714.52% in 2025.
  • Quarter analysis of 5 years shows Coherus Oncology's Consolidated Net Income stood at -$45.7 million in 2021, then decreased by 28.75% to -$58.9 million in 2022, then plummeted by 35.3% to -$79.7 million in 2023, then soared by 348.34% to $197.8 million in 2024, then tumbled by 95.46% to $9.0 million in 2025.
  • Its Consolidated Net Income stands at $9.0 million for Q3 2025, versus $342.6 million for Q2 2025 and -$9.2 million for Q1 2025.